Publications

Suh M, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. A systematic literature review of the burden of respiratory syncytial virus disease and health care utilization among United States infants younger than 1 year. J Infect Dis 226(Suppl 2):S195–S212; doi: 10.1093/infdis/jiac201. PMID: 35968876.

Suh M, Movva N, Jiang X, Reichert H, Bylsma LC, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus burden and healthcare utilization in United States infants, <1 year of age: Study of nationally representative databases, 2011–2019. J Infect Dis 226(Suppl 2):S184–S194; doi: 10.1093/infdis/jiac155. PMID: 35968879.

Movva N, Suh M, Reichert H, Hitze B, Sendak MP, Wolf Z, et al. 2022. Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: A retrospective cohort study of a health system. J Infect Dis 226(Suppl 2):S175–S183; doi: 10.1093/infdis/jiac220. PMID: 35968868.

Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus (RSV) is the leading cause of United States infant hospitalizations 2009–2019: A study of the National (Nationwide) Inpatient Sample. J Infect Dis 226(Suppl 2):S154–S163; doi: 10.1093/infdis/jiac120. PMID: 35968878.

Wheeler MW, Cortiñas Abrahantes J, Aerts M, Gift JS, Allen Davis J. 2022. Continuous model averaging for benchmark dose analysis: Averaging over distributional forms. Environmetrics 33(5):e2728; doi: 10.1002/env.2728. PMCID: PMC9799099.

House JS, Grimm FA, Klaren WD, Dalzell A, Kuchi S, Zhang S, Lenz K, Boogaard PJ, Ketelsegers HB, Gant TW, Wright FA, Rusyn I. 2022. Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays. ALTEX 39(3):388-404; doi: 10.14573/altex.2107051. PMID: 35288757.

Rankin DA, Haddadin Z, Lipworth L, Stahl AL, Fryzek J, Suh M, et al. 2022. Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee. Therapeut Adv Infect Dis 9(July 18):20499361221112171; doi: 10.1177/20499361221112171. PMID: 35875809.

Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K,…, Price C, et al. 2022. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis 25(3):444–452; doi: 10.1038/s41391-022-00553-2.

Tsvetkov L, Pittsenbarger J, Atsriku C, Devine P, Dingley K, et al. 2022. Inhibition of CDC7 with Sgr-2921 in AML models results in enhanced DNA damage and anti-leukemic activity as monotherapy and in combination with standard of care agents. Blood 140 (Supplement 1):5961–5962; doi: 10.1182/blood-2022-167239.

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salahuddin K, Prats J, et al. 2022. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: A US hospital perspective. Am J Cardiovasc Drugs 22(1):93-104; doi: 10.1007/s40256-021-00491-9. PMID: 34331235.

Alexander AW, Jensen IJ, Hathaway J, Srivastava K, Cyr PL, Sidonio RF, Batt K. 2022. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 28(5):518-527; doi: 10.18553/jmcp.2022.21197. PMID: 35343812.

Price C. 2022. Syntheses synthesized: A look back at Grant and Booth’s review typology. Evid-based Libr Info Prac 17(2):132–138; doi: 10.18438/eblip30093.

Coppi A, Davies R, Wegesser T, Ishida K, Karmel J, Han J, Aiello F, Xie Y…, Monticello TM, et al. 2022. Characterization of false positive, contaminant- driven mutagenicity in impurities associated with the sotorasib drug substance. Regul Toxicol Pharmacol 131(June):105162; doi: 10.1016/j.yrtph.2022.105162.

Reynolds JI, Vitek RA, Geiger PG, Johnson BP. 2022. Engineering epithelial-mesenchymal microtissues to study cell-cell interactions in development. Methods Med Biol 2403:201-213; doi: 10.1007/978-1-0716-1847-9_13. PMID: 34913124.

Flannery BM, Schaefer HR, Middleton KB. 2022. A scoping review of infant and children health effects associated with cadmium exposure. Regul Toxicol Pharmacol 131(Jun):105155; doi: 10.1016/j.yrtph.2022.105155. PMID: 35257832.

Rivera BN, Wilson LB, Kim DM, Pande P, Anderson KA, Tilton SC, Tanguay RL. 2022. A comparative multi-system approach to characterizing bioactivity of commonly occurring chemicals. Int J Environ Res Public Health 19(7):3829; doi: 10.3390/ijerph19073829. PMID: 35409514.

Lea IA, Pham LL, Antonijevic T, Thompson C, Borghoff SJ. 2022. Assessment of the applicability of the threshold of toxicological concern for per- and polyfluoroalkyl substances. Regul Toxicol Pharmacol 133(August):105190; doi: 10.1016/j.yrtph.2022.105190. PMID: 35662637.

Sacks NC, Healey BE, Raza S, Cyr PL, Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576; doi: 10.1182/bloodadvances.2021004364. PMID: 34807973.

Sheshadri A, Sacks NC, Healey B, Cyr P, Boerner G, Huang HJ. 2022. The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States. J Med Econ 25(1):650–659; doi: 10.1080/13696998.2022.2071065. PMID: 35502563.

Sheshadri A, Sacks NC, Healey BE, Raza S, Boerner G, Huang HJ. 2022. Lung function monitoring after lung transplantation and allogeneic hematopoietic stem cell transplantation. Clin Ther 44(5):755–765; doi: 10.1016/j.clinthera.2022.03.011. PMID: 35513911.